323 related articles for article (PubMed ID: 10975555)
21. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
[TBL] [Abstract][Full Text] [Related]
22. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells.
Wu XM; Liu X; Jiao QF; Fu SY; Bu YQ; Song FZ; Yi FP
Asian Pac J Cancer Prev; 2014; 15(6):2447-51. PubMed ID: 24761845
[TBL] [Abstract][Full Text] [Related]
24. Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.
Jabbar B; Rafique S; Salo-Ahen OMH; Ali A; Munir M; Idrees M; Mirza MU; Vanmeert M; Shah SZ; Jabbar I; Rana MA
Front Immunol; 2018; 9():3000. PubMed ID: 30619353
[TBL] [Abstract][Full Text] [Related]
25. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
26. HPV DNA vaccines.
Moniz M; Ling M; Hung CF; Wu TC
Front Biosci; 2003 Jan; 8():d55-68. PubMed ID: 12456324
[TBL] [Abstract][Full Text] [Related]
27. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
28. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
[TBL] [Abstract][Full Text] [Related]
29. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
30. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
31. Prevention of carcinoma of cervix with human papillomavirus vaccine.
Gavarasana S; Kalasapudi RS; Rao TD; Thirumala S
Indian J Cancer; 2000; 37(2-3):57-66. PubMed ID: 11876611
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection.
Haigh O; Kattenbelt J; Cochrane M; Thomson S; Gould A; Tindle R
Cancer Gene Ther; 2010 Oct; 17(10):708-20. PubMed ID: 20539319
[TBL] [Abstract][Full Text] [Related]
33. Preventative and therapeutic vaccines for cervical cancer.
Roden R; Wu TC
Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
[TBL] [Abstract][Full Text] [Related]
34. The use of vaccines in the prevention and treatment of cervical cancer.
Davidson EJ; Kitchener HC; Stern PL
Clin Oncol (R Coll Radiol); 2002 Jun; 14(3):193-200. PubMed ID: 12109821
[TBL] [Abstract][Full Text] [Related]
35. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
36. [Possibilities of vaccination against HPV infections in cervix carcinoma].
Gissmann L
Zentralbl Gynakol; 2001 May; 123(5):299-301. PubMed ID: 11449623
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Vaccines Against Human Papilloma Viruses: Achievements and Prospects.
Vonsky MS; Runov AL; Gordeychuk IV; Isaguliants MG
Biochemistry (Mosc); 2019 Jul; 84(7):800-816. PubMed ID: 31509730
[TBL] [Abstract][Full Text] [Related]
38. Papillomavirus vaccines.
Duggan-Keen MF; Brown MD; Stacey SN; Stern PL
Front Biosci; 1998 Dec; 3():D1192-208. PubMed ID: 9835649
[TBL] [Abstract][Full Text] [Related]
39. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
40. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
